European approval of avapritinib (Ayvakyt) for the treatment of gastrointestinal stromal tumours (GIST)

The European Commission has granted conditional marketing authorization for this protein kinase inhibitor as monotherapy for treatment of adults with unresectable or metastatic GIST harbouring the platelet-derived growth factor receptor alpha D842V mutation.

Source:

Biospace Inc.